Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Neurobo Pharmaceuticals Inc (NRBO)

3.93   -0.04 (-1.01%) 03-07 04:41
Open: 3.98 Pre. Close: 3.97
High: 4.1 Low: 3.63
Volume: 159,405 Market Cap: 87M
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.109 - 4.133 4.133 - 4.152
Low: 3.577 - 3.606 3.606 - 3.628
Close: 3.888 - 3.935 3.935 - 3.97

Technical analysis

as of: 2021-03-05 5:11:18 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 6.07     One year: 7.21
Support: Support1: 3.63    Support2: 3.02
Resistance: Resistance1: 5.20    Resistance2: 6.17
Pivot: 4.82
Moving Average: MA(5): 4.26     MA(20): 4.99
MA(100): 5.52     MA(250): 8.23
MACD: MACD(12,26): -0.38     Signal(9): -0.26
Stochastic oscillator: %K(14,3): 11.27     %D(3): 15.20
RSI: RSI(14): 31.94
52-week: High: 29.71  Low: 3.63  Change(%): -74.0
Average Vol(K): 3-Month: 41244  10-Days: 27306

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
NRBO has closed above bottom band by 10.9%. Bollinger Bands are 74.9% wider than normal. The large width of the bands suggest high volatility as compared to NRBO's normal range. The bands have been in this wide range for 4 bars. This is a sign that the current trend might continue.

Headline News

Fri, 05 Mar 2021
NeuroBo Pharmaceuticals to Participate in HC Wainwright Global Life Sciences Conference - PRNewswire

Fri, 05 Mar 2021
The Daily Biotech Pulse: Fulgent's Big Quarter, Gilead Awaits FDA Decision, Apellis Winds Up COVID-19 Study - Yahoo Finance

Thu, 04 Mar 2021
Neurobo Pharmaceuticals Inc (NRBO) Stock Falls -10.34% This Week; Should You Buy? - InvestorsObserver

Wed, 03 Mar 2021
Is Neurobo Pharmaceuticals Inc (NRBO) Stock a Bad Value Wednesday? - InvestorsObserver

Tue, 02 Mar 2021
Do Analysts Agree Tuesday on Neurobo Pharmaceuticals Inc (NRBO) Stock's Target Price? - InvestorsObserver

Tue, 23 Feb 2021
Is Neurobo Pharmaceuticals Inc (NRBO) Stock a Bad Value Tuesday? - InvestorsObserver

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 22
Shares Float (M) 5
% Held by Insiders 1.99
% Held by Institutions 6.45
Shares Short (K) 140
Shares Short P. Month (K) 122

Stock Financials

EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin
Operating Margin
Return on Assets (ttm) -36.9
Return on Equity (ttm) -160.2
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.460
Qtrly Earnings Growth
Operating Cash Flow (M) -10
Levered Free Cash Flow (M) -4

Stock Valuations

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow -8.99

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.